Business Wire

GSOA

Share
Satellite Operators join to shape the communications ecosystem of the future through the transformation of the EMEA Satellite Operators’ Association to the Global Satellite Operators’ Association

Chief Executives of the world’s leading satellite operators announced today in Paris on the occasion of World Satellite Business Week 2021 that ESOA, the EMEA Satellite Operators Association, is expanding to include satellite operators from all world regions and will change its name to GSOA, the Global Satellite Operators’ Association. They also announced that seven new members – Amazon, APT, ARSAT, Intersputnik, Lockheed Martin, Omnispace and Star One – had already agreed to join GSOA.

GSOA will remain the only CEO-driven satellite industry association. It will focus on a core mission of providing a unified voice and a platform for collaboration for satellite operators globally to ensure their continued success and for broadening the opportunities for policymakers and industry players to leverage satellite services to fulfil their objectives.

“The creation of GSOA reflects a strong belief in the satellite communications sector that a strong, global voice is needed to ensure that the sector is well positioned to helping create a more connected and sustainable world,” said Stephen Spengler, ESOA Chairman and CEO of Intelsat. “The fact that new members are already joining us is a demonstration of support for GSOA’s mission and the need to ensure that, together, we have a strong voice in shaping the communications ecosystem of the future.”

Leading Change

GSOA is structured to drive industry leadership in the face of three key trends: unparalleled innovation in the space sector, an insatiable demand for all types of connectivity, and a need to bring sustainability to space. In this regard, the GSOA Board has approved three broad industry goals.

GSOA is committed to:

On earth: extending connectivity globally where other networks don’t, connecting unconnected communities, schools, households, planes, ships, businesses, humanitarian agencies, peacekeepers and governments, aiming to increase the number of satellite data connections by 250% by 2030 and increase the data consumed by those connections 15 fold.

In space: preserving the space environment for future generations by designing, launching and operating satellites in a responsible way and minimising the creation of space debris.

For all: supporting the UN Sustainable Development Goals by providing access to secure, reliable and sustainable broadcast & broadband connectivity to people, schools, enterprises, organisations and devices wherever they may be, whether on the move, at work, or at play.

ESOA to GSOA

With the industry’s multi-orbit offering, the satellite sector will respond to the great majority of connectivity requirements presented by the data driven economy of tomorrow. From bridging crippling social, education, healthcare and other divides that exist due to the lack of communications infrastructure on all continents to enabling a host of 5G and IoT use cases for different vertical sectors.

Satellite operators will continue to build on the successes of ESOA which include providing the support the industry needed to push ahead with 5G standards and vital leadership on issues such as satellite spectrum and space sustainability. Through GSOA, the satellite sector will now be able to drive such global activities leveraging a global operator base.

GSOA will provide its members with the opportunity to shape the future of the satellite communications industry and the frameworks in which it operates by participating in key activities that impact the sector. Specifically, GSOA members will be able to engage in cross-sector initiatives, drive common positions, represent the industry on topics such as spectrum and 5G in events on all continents and contribute to ITU work concerning the development agenda, emergency communications and of course spectrum.

The association will continue to have a CEO-led Board, which has proved invaluable to the success of the ESOA to date, a strong Secretariat, and member-driven working groups that execute the broad agenda set by the Board.

This is an important change that will help ensure the industry is positioned well into the future ”, said Aarti Holla-Maini, the secretary general of ESOA. “We also recognize that there are other industry associations who will want to understand the implications of this change and we look forward to working with them to ensure the satellite communications sector has the strongest possible, unified global voice .”

The Global Satellite Operators Association now counts among its members: Airbus CIS, Amazon, Amos Spacecom, APT, Arabsat, Arsat, Avanti, Azercosmos, Echostar-Hughes, HellasSat, Hispasat, Inmarsat, Intelsat, Intersputnik, Lockheed Martin, Nigcomsat, Nilesat, Omnispace, OneWeb, Rascomstar, SES, SSI-Monacosat, Star One, Telenor, Telesat, Telespazio, Thuraya, Turksat, Viasat and Yahsat as well as representatives of the broader space industry including Airbus Defence and Space, Arianespace, Astroscale, Mansat, ST Engineering and Thales Alenia Space.

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Corcept Presents ESMO 2025 Late-Breaker: Relacorilant Demonstrates Benefit in Patients with Platinum-Resistant Ovarian Cancer with Prior PARP Inhibitor Treatment19.10.2025 11:15:00 CEST | Press release

New data from pivotal Phase 3 ROSELLA trial reinforce relacorilant plus nab-paclitaxel improves progression-free and overall survival in patients with platinum-resistant ovarian cancer, with no need for biomarker selection – including in people who progressed while on or after taking a PARP inhibitor, a patient population with particularly poor prognosis Corcept expands BELLA trial to three study arms: (i) platinum-resistant ovarian cancer, (ii) platinum-sensitive ovarian cancer and (iii) endometrial cancer Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today shared new late-breaking data from its pivotal Phase 3 ROSELLA trial of relacorilant plus nab-paclitaxel in patients with platinum-resistant ovarian cancer at the European Society for Medical Oncology (ESMO) 2025 Annual

Deciphera Presents 2-Year Efficacy and Safety Results from MOTION Phase 3 Study of ROMVIMZA™ (vimseltinib) in Patients with Tenosynovial Giant Cell Tumor (TGCT) at the European Society for Medical Oncology Congress 202518.10.2025 13:00:00 CEST | Press release

– Vimseltinib demonstrated statistically significant and clinically meaningful benefit vs placebo in antitumor response – Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the two-year efficacy and safety results from its MOTION Phase 3 study of vimseltinib in patients with TGCT in cases where surgical removal of the tumor is not an option will be presented as a poster during the 2025 European Society for Medical Oncology Congress (ESMO), taking place October 17-21 in Berlin, Germany. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251018921529/en/ “These long-term Phase 3 MOTION results add to the established body of evidence supporting vimseltinib as a best-in-class treatment for TGCT,” said Matthew L. Sherman, M.D., Chief Medical Officer of Deciphera. “TGCT often causes debilitating pain, stiffness and impaired mobility and these results demonstrate the dura

ProAmpac Acquires International Paper’s Bag Converting Operations17.10.2025 16:09:00 CEST | Press release

ProAmpac, a global leader in flexible packaging and material science, has acquired the bag converting operations of International Paper (“IP”), a global leader in sustainable packaging. The acquisition expands ProAmpac’s converting capabilities, further advancing the company’s Fiberization of Packaging® strategy and enhancing its ability to deliver customized bag solutions for the grocery, convenience store, and quick-service restaurant markets. “Global demand for reliable, recyclable paper packaging continues to grow rapidly amid evolving consumer expectations and market trends redefining recyclability,” stated Greg Tucker, ProAmpac founder, vice chairman, and chief executive officer. “ProAmpac’s acquisition of IP’s bag operation supports our Fiberization of Packaging initiatives, helping us better serve customers by extending our expertise in material science to the US west coast with additional capabilities and redundancies,” continued Tucker. “IP’s bag business is strong, being bui

Pimicotinib Treatment Demonstrates Deep and Durable Tumor Responses and Continued Improvements in Pain and Function for Patients with TGCT17.10.2025 16:00:00 CEST | Press release

With median follow-up of 14.3 months, pimicotinib demonstrated increasing ORR over time, from 54% at Week 25 to 76.2%Global Phase 3 MANEUVER study demonstrated ongoing improvements in key secondary endpoints including pain and functionApplication for marketing authorization under review by China National Medical Products Administration (NMPA), with additional applications planned in the U.S. and other marketsNot intended for Canada-, UK- or US-based media Merck, a leading science and technology company, today announced the presentation of longer-term results from the global Phase 3 MANEUVER trial evaluating pimicotinib, an investigational colony stimulating factor-1 receptor (CSF-1R) inhibitor in development by Abbisko Therapeutics Co., Ltd., for the treatment of patients with tenosynovial giant cell tumor (TGCT). This latest analysis showed that, with a median follow-up of 14.3 months, the objective response rate (ORR) for people treated with pimicotinib from the beginning of the stud

Vertex Announces Progress in Povetacicept Development Program and Presentation of New Data at American Society of Nephrology Kidney Week17.10.2025 15:04:00 CEST | Press release

- Food and Drug Administration grants rolling review of Biologics License Application for povetacicept in IgA nephropathy; Vertex to submit first module before end of year - - Second pivotal development program of povetacicept underway with Phase 2b/3 trial initiation in primary membranous nephropathy - - Updated data from RUBY-3 trial of povetacicept accepted for late breaking oral presentation; inaxaplin study design and APOL1-mediated kidney disease related data accepted for poster presentation - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced several important updates across its development program for povetacicept (pove), an investigational recombinant fusion protein therapeutic and dual antagonist of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines. Pove has demonstrated best-in-class potential in IgA nephropathy (IgAN) and primary membranous nephropathy (pMN) and has pipeline-in-a-product potential across a range of B c

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye